脑膜瘤的临床病理及PCNA标记的研究  

Study of clinical pathology and proliferating cell nuclear antigen (PNC A) in meningiomas

作　　者：张龙[1] 薛德麟[1] 胡学信 

机构地区：[1]同济医科大学同济医院,武汉430030 [2]解放军第152医院,河南平顶山467000

出　　处：《临床肿瘤学杂志》2001年第1期13-14,共2页Chinese Clinical Oncology

摘　　要：目的:为能准确预见脑膜瘤的生物学行为,并对术后辅助治疗与否提供参考依据。方法:对35例脑膜瘤组织行增殖细胞核抗原（PCNA）免疫组化染色,并结合图像定量分析及常规病理分型进行研究。结果:PCNA标记指数随肿瘤恶性程度而增高。结论:PCNA免疫组化检测方法能较好地反映脑膜瘤的增殖活力,可作为术后辅助治疗及定期复查与否的可靠指标。Objective: To Predict the meningioma biological behavior and provide information for more radiological therapy to the tumors in postoperation. Methods: 35 cases of meningiomas were studied by immunohistochemical method combining image quantity analysis and routine pathological examination.Results:The PCNA index was higher in malignant meningiomas.Conclusion: The PCNA index assay may correctly reflect the proliferating activity of the meningioma, it may be adopted as an indictor for subsequent therapy and countercheck of the operated tumors.

关 键 词：脑膜瘤 病理 增殖细胞核抗原 PCNA 肿瘤标记 

分 类 号：R739.45[医药卫生—肿瘤]